The esteemed scientist, one of the world’s leading experts in molecular biology, explains how disruptions at the cellular ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

Genetic editing holds promise to treat incurable diseases, but the most popular method—CRISPR—sometimes does more harm than ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

Genetic editing holds promise to treat incurable diseases, but the most popular method - CRISPR - sometimes does more harm ...

Forget the glorious successes of past breakthroughs—the real justification for research investment is what we get for our ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

From the currently used sputum testing, soon tuberculosis screening can be done via a simple tongue swab, according to a ...

When brain development gets off to a bad start, the consequences are lifelong. One example is a condition called SCN2A ...